Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Nature Medicine · 2025-03 · 31 (3) · 797-806
DOI: 10.1038/s41591-024-03426-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Medicine, online erschienen am 30.01.2025. Verfasst von Eugene P Duff und 11 weiteren Autor:innen. Beteiligte Einrichtung: UK Dementia Research Institute Centre at Imperial College London, London, UK. e.duff@imperial.ac.uk. Hauptthemen laut MEDLINE: COVID-19, Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Previous studies have suggested that systemic viral infections may increase risks of dementia. Whether this holds true for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infections is unknown. Determining this is important for anticipating the potential future incidence of dementia. To begin to do this, we measured plasma biomarkers linked to Alzheimer’s disease pathology in the UK Biobank before and after serology-confirmed SARS-CoV-2 infections. SARS-CoV-2 infection was associated with biomarkers associated with β-amyloid pathology: reduced plasma Aβ42:Aβ40 ratio and, in more vulnerable participants, lower plasma Aβ42 and higher plasma pTau-181. The plasma biomarker changes were greater in participants who had been hospitalized with COVID-19 or had reported hypertension previously. We showed that the changes in biomarkers were linked to brain structural imaging patterns associated with Alzheimer’s disease, lower cognitive test scores and poorer overall health evaluations. Our data from this post hoc case–control matched study thus provide observational biomarker evidence that SARS-CoV-2 infection can be associated with greater brain β-amyloid pathology in older adults. While these results do not establish causality, they suggest that SARS-CoV-2 (and possibly other systemic inflammatory diseases) may increase the risk of future Alzheimer’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UK Dementia Research Institute Centre at Imperial College London, London, UK. e.duff@imperial.ac.uk.
- Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK. e.duff@imperial.ac.uk.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, UK.
- UK Dementia Research Institute Centre at UCL, London, UK.
Zitieren
APA
Duff, E. P., Zetterberg, H., Heslegrave, A., Dehghan, A., Elliott, P., Allen, N., Runz, H., Laban, R., Veleva, E., Whelan, C. D., Sun, B. B., & Matthews, P. M. (2025). Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. Nature Medicine, 31(3), 797-806. https://doi.org/10.1038/s41591-024-03426-4
Vancouver
Duff EP, Zetterberg H, Heslegrave A, Dehghan A, Elliott P, Allen N, et al. Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. Nature Medicine. 2025;31(3):797-806. doi:10.1038/s41591-024-03426-4
BibTeX
@article{Duff2025,
author = {Duff, Eugene P and Zetterberg, Henrik and Heslegrave, Amanda and Dehghan, Abbas and Elliott, Paul and Allen, Naomi and Runz, Heiko and Laban, Rhiannon and Veleva, Elena and Whelan, Christopher D and Sun, Benjamin B and Matthews, Paul M},
title = {Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {3},
pages = {797--806},
doi = {10.1038/s41591-024-03426-4}
}
EUVIMED